Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.

@article{Khan2003SuicideRI,
  title={Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.},
  author={Arif Khan and Shirin R F Khan and Russell L. Kolts and Walter Armin Brown},
  journal={The American journal of psychiatry},
  year={2003},
  volume={160 4},
  pages={
          790-2
        }
}
OBJECTIVE Previous reports suggesting that selective serotonin reuptake inhibitor (SSRI) use is associated with increased suicidal risk have not assessed completed suicides. The authors analyzed reports from randomized controlled trials to compare suicide rates among depressed patients assigned to an SSRI, other antidepressants, or placebo. METHOD Food and Drug Administration (FDA) summary reports of the controlled clinical trials for nine modern FDA-approved antidepressants provided data for… Expand
Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review
TLDR
No evidence that SSRIs increased the risk of suicide is found, but important protective or hazardous effects cannot be excluded, and larger trials with longer follow up are required to assess the balance of risks and benefits fully. Expand
Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials
TLDR
The authors' systematic review, which included a total of 87 650 patients, documented an association between suicide attempts and the use of SSRIs. Expand
MHRA's safety review randomised controlled trials submitted to the company data from placebo controlled, and suicide in adults: meta-analysis of drug Selective serotonin reuptake inhibitors (SSRIs)
TLDR
No evidence that SSRIs increased the risk of suicide is found, but important protective or hazardous effects cannot be excluded, and larger trials with longer follow up are required to assess the balance of risks and benefits fully. Expand
Primary care Association between suicide attempts and selective serotonin reuptake inhibitors : systematic review of randomised controlled trials
Objective To establish whether an association exists between use of selective serotonin reuptake inhibitors (SSRIs) and suicide attempts. Design Systematic review of randomised controlled trials.Expand
How have the Selective Serotonin Reuptake Inhibitor Antidepressants Affected Suicide Mortality?
TLDR
Evidence on two claims that have been made about the effects of selective serotonin reuptake inhibitor (SSRI) antidepressants are reviewed, meta-analyses of RCTs suggest that SSRIs increase suicide ideation compared with placebo but the observational studies suggest thatSSRIs do not increase suicide risk more than older antidepressants. Expand
What is the Risk of Suicidality in Depressive Adult Patients Using SSRIs?A Meta-Analysis of RCTs
TLDR
Findings support that there is no increased risk of suicidality in adult patients treated with SSRI for depression. Expand
The risk of suicide with selective serotonin reuptake inhibitors in the elderly.
TLDR
Initiation of SSRI therapy is associated with an increased risk of suicide during the first month of therapy compared with other antidepressants, suggesting that an idiosyncratic response to these agents may provoke suicide in a vulnerable subgroup of patients. Expand
Duloxetine: Meta-analyses of Suicidal Behaviors and Ideation in Clinical Trials for Major Depressive Disorder
TLDR
No evidence of an increased risk of suicidal behaviors or ideation during treatment with duloxetine compared with placebo in MDD patients is found, and changes in Hamilton Depression Scale Item-3 suicidality scores had more improvement and less worsening of suicidal ideation with dULoxETine than placebo. Expand
[Antidepressants and suicidality. Risk-benefit analysis].
Reanalyses of placebo-controlled trials reveal an increased risk of suicidal ideations or parasuicidal acts in children and adolescents under treatment with selective serotonin reuptake inhibitorsExpand
Ecological Studies of Antidepressant Treatment and Suicidal Risks
TLDR
Overall, these findings yield limited and inconsistent support for the hypothesis that increased use of modern antidepressants might limit suicide risk, and no evidence that the risk increased. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 11 REFERENCES
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.
TLDR
Assessment of suicides, suicide attempts, and depressive symptom reduction in studies of 7 new antidepressants using the Food and Drug Administration database may help inform discussions about the use of placebo in antidepressant clinical trials. Expand
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database.
TLDR
Suicide risk and symptom reduction among placebo-treated patients participating in antidepressant clinical trials for two recently approved antidepressants, venlafaxine ER and citalopram, which were unavailable during the previous study are assessed. Expand
Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
TLDR
Data from these trials do not show that fluoxetine is associated with an increased risk of suicidal acts or emergence of substantial suicidal thoughts among depressed patients. Expand
Suicide as an outcome for mental disorders. A meta-analysis.
TLDR
If these results can be generalised then virtually all mental disorders have an increased risk of suicide excepting mental retardation and dementia. Expand
Suicide in the course of the treatment of depression
TLDR
It is concluded that antidepressants can be implicated in some cases of suicide during treatment and modifications of clinical trial methods and pharmacogenetic studies would yield a richer data set to explore this issue further. Expand
Failure to warn.
  • A. R. Gold
  • Medicine
  • Journal of the American Optometric Association
  • 1986
TLDR
In January 1988, a selective serotonin reuptake inhibiting (SSRI) antidepressant, Prozac, was launched in America and during the 1990s, this brand name had all the prominence Valium once had but patients at risk were largely inpatients, being given regimens that degraded any capacity to act. Expand
Functional effects of agents differentially selective to noradrenergic or serotonergic systems
Background. The diversity of pharmacological actions of antidepressants suggests that they may bring about their clinical effects by different functional means. Methods. Twenty healthy volunteersExpand
Emergence of antidepressant induced suicidality
TLDR
Ric or akathisic respow;es on their own to either drug did not lead Co suIdda1, and some agreement as rcg;u:-ds (he: probable mechanism l=ding to the difficulties) was some agreement. Expand
Emergence of intense suicidal preoccupation during fluoxetine treatment.
TLDR
Six depressed patients free of recent serious suicidal ideation developed intense, violent suicidal preoccupation after 2-7 weeks of fluoxetine treatment, and none of them had ever experienced a similar state during treatment with any other psychotropic drug. Expand
5 US Congress
  • 552
  • 1996
...
1
2
...